Wall Street brokerages forecast that BioScrip Inc (NASDAQ:BIOS) will post ($0.10) earnings per share for the current fiscal quarter, Zacks reports. Three analysts have provided estimates for BioScrip’s earnings, with the highest EPS estimate coming in at ($0.10) and the lowest estimate coming in at ($0.11). BioScrip reported earnings per share of ($0.11) during the same quarter last year, which suggests a positive year-over-year growth rate of 9.1%. The company is scheduled to issue its next earnings report on Tuesday, August 14th.
According to Zacks, analysts expect that BioScrip will report full-year earnings of ($0.31) per share for the current financial year, with EPS estimates ranging from ($0.32) to ($0.29). For the next financial year, analysts forecast that the company will report earnings of ($0.14) per share, with EPS estimates ranging from ($0.18) to ($0.11). Zacks’ earnings per share averages are an average based on a survey of sell-side research analysts that follow BioScrip.
BioScrip (NASDAQ:BIOS) last issued its earnings results on Thursday, May 10th. The company reported ($0.12) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.11) by ($0.01). The business had revenue of $168.60 million for the quarter, compared to analyst estimates of $164.72 million. The business’s revenue was down 22.6% on a year-over-year basis. During the same period in the previous year, the business earned ($0.18) earnings per share.
Several brokerages have issued reports on BIOS. BidaskClub raised shares of BioScrip from a “buy” rating to a “strong-buy” rating in a report on Thursday. Zacks Investment Research raised shares of BioScrip from a “sell” rating to a “hold” rating in a report on Tuesday, May 15th. Craig Hallum reaffirmed a “buy” rating and issued a $3.50 target price on shares of BioScrip in a report on Thursday, March 8th. Finally, SunTrust Banks reaffirmed a “buy” rating and issued a $3.25 target price on shares of BioScrip in a report on Thursday, March 8th. Two investment analysts have rated the stock with a hold rating, three have given a buy rating and one has assigned a strong buy rating to the company. The company presently has a consensus rating of “Buy” and a consensus target price of $3.44.
Institutional investors have recently modified their holdings of the business. Gotham Asset Management LLC purchased a new position in BioScrip in the fourth quarter worth about $114,000. MetLife Investment Advisors LLC purchased a new position in shares of BioScrip during the fourth quarter valued at approximately $174,000. Two Sigma Advisers LP raised its holdings in shares of BioScrip by 100.4% during the fourth quarter. Two Sigma Advisers LP now owns 128,245 shares of the company’s stock valued at $373,000 after purchasing an additional 64,238 shares during the last quarter. Wells Fargo & Company MN raised its holdings in shares of BioScrip by 34.4% during the fourth quarter. Wells Fargo & Company MN now owns 217,450 shares of the company’s stock valued at $634,000 after purchasing an additional 55,636 shares during the last quarter. Finally, Cambridge Investment Research Advisors Inc. purchased a new position in shares of BioScrip during the first quarter valued at approximately $635,000. 85.46% of the stock is owned by institutional investors and hedge funds.
Shares of BioScrip stock opened at $2.93 on Wednesday. The company has a debt-to-equity ratio of -4.79, a quick ratio of 1.30 and a current ratio of 1.70. BioScrip has a 52-week low of $1.80 and a 52-week high of $3.39.
BioScrip, Inc provides infusion solutions in the United States. It engages in the preparation, delivery, administration, and clinical monitoring of pharmaceutical treatments that are administered to a patient through intravenous, subcutaneous, intramuscular, intra-spinal, and enteral methods. The company is primarily involved in the intravenous administration of medications to treat a range of acute and chronic conditions, such as infections, nutritional deficiencies, immunologic and neurologic disorders, cancer, pain, and palliative care.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for BioScrip Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioScrip and related companies with MarketBeat.com's FREE daily email newsletter.